Hatem Soliman, MD
Enriched profileSenior Member, Breast Oncology and Immunology Departments; Medical Director, Clinical Trials Office, Moffitt Cancer Center · Moffitt Cancer Center
Hatem Soliman is Senior Member, Breast Oncology and Immunology Departments; Medical Director, Clinical Trials Office, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 283 publications with 12,659 citations (h-index 47); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Hatem Soliman, MD, is Senior Member, Breast Oncology and Immunology Departments at Moffitt Cancer Center, Tampa, FL. The public record shows 283 publications with 12,659 citations (h-index 47), centered on Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 19 companies, 1 NIH-funded awards (2020–2026).
- Most recent indexed publication: 2025 · JCO precision oncology
- Top research focus: Cancer Immunotherapy and Biomarkers
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 95.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Sponsor: Stemline Therapeutics, Inc.
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Industry payments
Updated 16 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Daiichi Sankyo Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
81.5%Aromatase Inhibitor61%Letrozole55%Anastrozole30%Exemestane15%Part D<11 patientsKinase inhibitor10.4%Kisqali58%Tukysa42%Part D<11 patients+ 1 more class in this area
Nervous system
12.9%Gabapentinoids8.4%Gabapentin100%Part D<11 patientsPhenothiazine4.4%Prochlorperazine Maleate100%Part D<11 patientsBlood & clotting
5.6%Factor Xa inhibitor5.6%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2020–2026 per NIH RePORTER. The latest:
Congress activity
Updated 16 Oct 2026
111 congress contributions (2009–2026) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial).
ASCO Annual Meeting
ASCO2026Co-author - Patterns of failure and outcomes in triple-negative compared to estrogen receptor–positive breast cancer.
ASCO Annual Meeting
ASCO2026Co-author - Phase III trial of brain MRI surveillance in stage IV breast cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Nature medicine
Clinical Trial2025 - Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.
Nature medicine
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyArticle1,624 citations2020
- 02Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in OncologyArticle1,617 citations2018
- 03Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle971 citations2022
- 04Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in OncologyArticle600 citations2024
- 05NCCN Guidelines Insights: Breast Cancer, Version 1.2017Article544 citations2017
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/hatem-soliman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Hatem-Soliman-14164986
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/moffittcancercenter_dr-hatem-soliman-at-asco-2023-activity-7071204082807398400-NA5f
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
- Board Certified
Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗ - Residency
Internal Medicine, University of South Florida
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - Fellowship
Hematology/Oncology, University of South Florida
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Editorial & leadership roles
journal and society appointments- Chair
State of the Science Summit – Breast Cancer (OncLive CME session)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Secondary affiliations
appointments beyond the home institution- Senior Professor
Department of Oncologic Sciences, University of South Florida Morsani College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Andrew Brohl, MD
Moffitt Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles